Skip to main content
SpringerLink
Log in

Long Term Aspirin in the Prevention of Cardiovascular Disorders

Recent Developments and Variations on a Theme

  • Leading Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Conclusion

Aspirin should be considered to have established efficacy as treatment for the long term prevention of cardiovascular events. However, no controlled studies of aspirin administration were extended beyond 5 years, and its use for a longer period is consequently empiric. Presently, its risk-benefit profile supports its indefinite use in high risk patients, but not in the healthy population. Alternative formulations of aspirin, drug combination strategies as well as new, more potent antithrombotic agents, such as orally bioavailable thrombin inhibitors and glycoprotein IIb/IIIa antagonists, are under investigation. These strategies will probably widen the indications for long term platelet inhibition. Results achieved with the intravenously administered monoclonal antibody abciximab, have demonstrated that the efficacy of IIb/IIIa antagonists is additive to that of aspirin.[15] Oral IIb/III antagonists have already been shown to induce dose-dependent inhibition of platelet aggregation for an extended period of time[53] and are currently in clinical development. Long term treatment with these compounds might be beneficial in indications which aspirin lacks efficacy, such as in the prevention of late thrombotic events and/or restenosis following coronary angioplasty.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983; 309: 396–403

    Article  PubMed  Google Scholar 

  2. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian Multicenter Trial. N Engl J Med 1985; 313: 1369–75

    Article  PubMed  CAS  Google Scholar 

  3. Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320–31

    Article  Google Scholar 

  4. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60

    Google Scholar 

  5. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy — I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106

    Article  Google Scholar 

  6. The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978; 299: 53–9

    Article  Google Scholar 

  7. The Dutch TIA Trial Study Group. A comparison of 2 doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261–6

    Article  Google Scholar 

  8. The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345–9

    Article  Google Scholar 

  9. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–30

    Article  Google Scholar 

  10. Wallentin LC and the Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: Long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol 1991; 18: 1587–93

    Article  Google Scholar 

  11. Bourassa MG, Schwartz L, Lesperance J, et al. Prevention of acute complications after percutaneous transluminal coronary angioplasty. Thromb Res Suppl 1990; 12: 51–8

    Article  PubMed  CAS  Google Scholar 

  12. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714–9

    Article  PubMed  CAS  Google Scholar 

  13. Serruys PW, Rutsch W, Heyndrickx GR, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Circulation 1991; 84: 1568–80

    Article  PubMed  CAS  Google Scholar 

  14. Serruys PW, Klein W, Tijssen JPG, et al. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial. Circulation 1993; 88: 1588–601

    Article  PubMed  CAS  Google Scholar 

  15. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956–61

    Article  Google Scholar 

  16. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881–6

    Article  PubMed  CAS  Google Scholar 

  17. Petersen P, Godtfredsen J, Boysen G, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989; 1: 175–9

    Article  PubMed  CAS  Google Scholar 

  18. SPAF — Stroke Prevention in Atrial Fibrillation Study Group. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med 1990; 322: 863–8

    Google Scholar 

  19. SPAF — Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991; 84: 527–39

    Article  Google Scholar 

  20. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–62

    Google Scholar 

  21. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med 1989; 321: 129–35

    Article  Google Scholar 

  22. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313–6

    Article  PubMed  CAS  Google Scholar 

  23. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993; 35: 219–26

    Article  PubMed  CAS  Google Scholar 

  24. Braden GA, Knapp HR, FitzGerald GA. Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. Circulation 1991; 84: 679–85

    Article  PubMed  CAS  Google Scholar 

  25. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366–72

    Article  PubMed  CAS  Google Scholar 

  26. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206–11

    Article  PubMed  CAS  Google Scholar 

  27. Clarke RJ, Mayo G, Price P, et al. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137–41

    Article  PubMed  CAS  Google Scholar 

  28. Keimowitz RM, Pulvermacher G, Mayo G, et al. Transdermal modification of platelet function: a dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis. Circulation 1993; 88: 556–61

    Article  PubMed  CAS  Google Scholar 

  29. Turpie AGG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329: 524–9

    Article  PubMed  CAS  Google Scholar 

  30. Bloomfield P, Wheatley DJ, Prescott RJ, et al. Twelve year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses. N Engl J Med 1991; 324: 573–9

    Article  PubMed  CAS  Google Scholar 

  31. Cannegieter SC, Rosendaal FR, Briët E. Thrombo-embolic and bleeding complications in patients with mechanical heart valve prostheses: review and meta-analysis. Circulation 1994; 89: 635–41

    Article  PubMed  CAS  Google Scholar 

  32. Goodman SG, Langer A, Durica SS, et al. Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Am J Cardiol 1994; 74: 657–61

    Article  PubMed  CAS  Google Scholar 

  33. Meade TW, Roderick PJ, Brennan PJ, et al. Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemost 1992; 68: 1–6

    PubMed  CAS  Google Scholar 

  34. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231: 232–5

    CAS  Google Scholar 

  35. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on platelets. Acetylation of a particular fraction protein. J Clin Invest 1975; 56: 624–32

    Article  PubMed  CAS  Google Scholar 

  36. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS-10, a phorbolester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266: 12866–72

    PubMed  CAS  Google Scholar 

  37. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992; 89: 7384–8

    Article  PubMed  CAS  Google Scholar 

  38. Yokoyama C, Tanabe T. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun 1989; 165: 888–94

    Article  PubMed  CAS  Google Scholar 

  39. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228–32

    Article  PubMed  CAS  Google Scholar 

  40. Rimarachin JA, Jacobson JA, Szabo P, et al. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb 1994; 14: 1021–31

    Article  PubMed  CAS  Google Scholar 

  41. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 399–404

    Google Scholar 

  42. Thun MJ, Namboodiri MM, Heath Jr CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593–6

    Article  PubMed  CAS  Google Scholar 

  43. Rosenberg L, Palmer JR, Zauber AG, et al. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83: 355–8

    Article  PubMed  CAS  Google Scholar 

  44. Waterhouse D. Aspirin, NSAIDs and risk reduction of colorectal cancer. Arch Intern Med 1994; 154: 366–8

    Article  PubMed  CAS  Google Scholar 

  45. Winde G, Gumbinger HG, Osswald H, et al. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis; clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis 1993; 8: 13–7

    Article  PubMed  CAS  Google Scholar 

  46. Spagnesi MT, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994; 106: 362–6

    PubMed  CAS  Google Scholar 

  47. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183–8

    PubMed  CAS  Google Scholar 

  48. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994; 90: 11693–7

    Article  Google Scholar 

  49. Laneuville O, Breuer DK, Dewitt DL, et al. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994; 271: 927–34

    PubMed  CAS  Google Scholar 

  50. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271: 1705–12

    PubMed  CAS  Google Scholar 

  51. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994; 265: 956–9

    Article  PubMed  CAS  Google Scholar 

  52. Weber C, Erl W, Pietsch A, et al. Aspirin inhibits nuclear factor-κB mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 1995; 91: 1914–7

    Article  PubMed  CAS  Google Scholar 

  53. Szalony JA, Haas NF, Salyers AK, et al. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. Circulation 1995; 91: 411–6

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA

    Francesca Catella-Lawson & Garret A. FitzGerald

Authors
  1. Francesca Catella-Lawson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Garret A. FitzGerald
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Catella-Lawson, F., FitzGerald, G.A. Long Term Aspirin in the Prevention of Cardiovascular Disorders. Drug-Safety 13, 69–75 (1995). https://doi.org/10.2165/00002018-199513020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199513020-00001

Search

Navigation